<DOC>
	<DOC>NCT01574872</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of Aerosal® compared to placebo in the prognosis of inverse psoriasis or sebopsoriasis present for at least one year</brief_summary>
	<brief_title>Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dermatitis, Seborrheic</mesh_term>
	<criteria>Inverse Psoriasis or Sebopsoriasis lasting from at one year At least 1% of total body surface area involvement Suspension for more than 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporin, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB) Patients with acute bronchopulmonary disease, tuberculosis, severe hypertension, hyperthyroidism, cancer (chemotherapy), intoxication, heart failure Iodine allergy Women who are pregnant or planning to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>salt</keyword>
	<keyword>sodium chloride</keyword>
</DOC>